Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy

Table 1 Patients’ demographic and clinical features

Patients’ demographic and clinical features
Gender	n (%)
Male	71 (69.6)
Female	31 (30.4)
Age	63.37 ± 10.21; (35-81)
Primary localization	n (%)
Rectum	42 (41.2)
Left colon	44 (43.1)
Right colon	16 (15.7)
Localization of metastasis	n (%)
Liver	91 (89.2)
Lung	38 (37.3)
Peritoneum	13 (12.7)
Lymph nodes	38 (37.3)
Tumour grade	n (%)
HG1	51 (50.0)
HG2	45 (44.1)
HG3	6 (5.9)
Chemotherapy 1st-line
Fluoropyrimidines + oxaliplatin	61 (59.8)
Fluoropyrimidines + irinotecan	14 (13.7)
Bevacizumab + (fluoropyrimidines + oxaliplatin); or (fluoropyrimidines + irinotecan)	20 (19.6)
EGFR inhibitors + (fluoropyrimidines + oxaliplatin); or (fluoropyrimidines + irinotecan)	4 (6.9)
Chemotherapy 1st-line (cont) or 2nd-line	n (%)
Fluoropyrimidines + oxaliplatin	53 (52.0)
Fluoropyrimidines + irinotecan	21 (20.6)
Bevacizumab + (fluoropyrimidines + oxaliplatin); or (fluoropyrimidines + irinotecan)	15 (14.7)
EGFR inhibitors + (fluoropyrimidines + oxaliplatin); or (fluoropyrimidines + irinotecan)	13 (12.7)

Data are presented as the mean ± SD or n (%).